1. Home
  2. EVMN

as of 06-30-2026 4:00pm EST

$13.32
$1.73
-11.50%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.

Founded: 2020 Country:
United States
United States
Employees: 48 City: PALO ALTO
Market Cap: 869.1M IPO Year: N/A
Target Price: $43.88 AVG Volume (30 days): 1.0M
Analyst Decision: Strong Buy Number of Analysts: 10
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $13.88 - $33.20 Next Earning Date: 06-11-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

AI-Powered EVMN Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 20 hours ago

AI Recommendation

sell
Model Accuracy: 75.00%
75.00%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Share on Social Networks: